Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Vertex Pharmaceuticals’ CRISPR-based therapy made history as ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...